Empaglifozin (Jardiance®). HTA ID: 22068

Assessment Status Rapid review complete
HTA ID 22068
Drug Empagliflozin
Brand Jardiance®
Indication For the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40%
Assessment Process
Rapid review commissioned 02/11/2022
Rapid review completed 02/12/2022
Rapid review outcome A full HTA is not recommended. The NCPE recommends that empagliflozin for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40% be considered for reimbursement*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.